Published: 2019-03-27

HLA-B*44 allele associated with clinical parameters in HIV-1 infected Moroccan cohort

Fatima Youssoufi, Hicham El Annaz, Abdelilah Laraqui, Reda Tagajdid, Rachid Abi, Safae Elkochri, Rachid Frikh, Tahar Bajjou, Naoufal Hjira, Yassine Sekhsokh, Saad Mrani


Background: The human leukocyte antigen-B*44 (HLA-B*44) allele has been reported to have promising results in the control of human immunodeficiency virus-1 (HIV-1) infection and associated with protection against HIV-1 disease progression. In the Moroccan HIV-1 infected patients, the contribution of this allele has not been established. This study aimed to evaluate the distribution of HLA-B*44 allele among HIV-1-infected in Morocco. Additionally, investigate HLA-B*44 allele association with demographical and HIV clinical parameters.

Methods: One hundred and sixty-seven HIV-1 infected, antiretroviral naive individuals were enrolled in this study. The HLA-B*44 allele screening was performed using the PCR amplification.

Results: Of the 167 individuals genotyped, 26 (16%) of them expressing the HLA-B*44 allele. Clinical stages at diagnosis, median pre-treatment HIV viral load (pVL) and CD4 T cell counts differ significantly (p = 0.0001, p=0.001 and p=0.0001 respectively) between the patients who had been expressing the HLA-B*44 allele and patients who had not been expressing this allele. The presence of HLA-B*44 allele was significantly associated with pVL and CD4 T cell counts (p=0.004 and p=0.0001 respectively). The bivariate analysis has showed that the expression of the HLA-B*44 allele was strongly associated with advanced HIV infection (Odd ratio (OR) 0.12 (95% confidence interval (CI) 0.04-0.37), p=0.0001).

Conclusions: Author have described for the first time in Morocco the association of the HLA-B*44 allele with the clinical parameters of HIV infection. These results expand the knowledge of the distribution and effect of this allele in the Moroccan population.


HLA-B*44 allele, HIV infection, Morocco

Full Text:



Zhu BF, Yang G, Shen CM, Qin HX, Liu SZ, Deng YJ. Distribution of HLA-A and -B alleles and haplotypes in the Yi ethnic minority of Yunnan, China: relationship to other populations. J Zhejiang Univ-Sci B. 2010 Feb;11(2):127-35.

Ozbek P. Dynamic characterization of HLA-B* 44 alleles: a comparative molecular dynamics simulation study. Computational Biol Chem. 2016;62:12-6.

SGE Marsh, ED Albert, WF Bodmer, RE Bontrop, B Dupont, HA Erlich, et al. Nomenclature for factors of the HLA system. Tissue Antigens. 2010;75:291-455.

Ostermeir K, Springer S, Zacharias M. Coupling between side chain interactions and binding pocket flexibility in HLA-B* 44: 02 molecules investigated by molecular dynamics simulations. Molecular Immunol. 2015;63(2):312-9.

Silva EM, Acosta AX, Santos EJ, Netto EM, Lemaire DC, Oliveira AS, et al. HLA-Bw4-B* 57 and Cw* 18 alleles are associated with plasma viral load modulation in HIV-1 infected individuals in Salvador, Brazil. Braz J Inf Dis. 2010;14(5):468-75.

Chaudhari DV, Chavan VR, Ahir SP, Kerkar SC, Mehta PR, Mania-Pramanik J. Human leukocyte antigen B distribution in HIV discordant cohort from India. Immunol Letters. 2013;156(1-2):1-6.

Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. New Eng J Med. 2001;344(22):1668-75.

Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O’Brien S, Andrieu JM, et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol. 1999;162(11):6942-6.

O'Brien SJ, Gao X, Carrington M. HLA and AIDS: a cautionary tale. Trends Mol Med. 2001;7(9):379-81.

Tang J, Cormier E, Gilmour J, Price MA, Prentice HA, Song W, et al. Human leukocyte antigen variants B* 44 and B* 57 are consistently favourable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes. J Virol. 2011;85(17):8894-902.

Zhang X, Huang X, Xia W, Li W, Zhang T, Wu H, et al. HLA-B* 44 is associated with a lower viral set point and slow CD4 decline in a cohort of Chinese homosexual men acutely infected with HIV-1. Clin Vaccine Immunol. 2013;20(7):1048-54.

Imanishi T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. HLA. 1991. 1992;1:1065-220.

Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, Leung JY, et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proceedings National Acad Sci. 2001;98(9):5140-5.

Herman J, Van Der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, et al. A peptide encoded by the human MAGE3 gene and presented by HLA-1344 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics. 1996;43(6):377-83.

Biasin M, De Luca M, Gnudi F, Clerici M. The genetic basis of resistance to HIV infection and disease progression. Expert Rev Clin Immunol. 2013;9(4):319-34.

Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, Ndung'u T, et al. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J Virol. 2010;84(19):9879-88.

Brick C, Atouf O, Bouayad A, Essakalli M. Moroccan study of HLA (-A,-B,-C,-DR,-DQ) polymorphism in 647 unrelated controls: Updating data. Mol Cellular Probes. 2015;29(4):197-207.

Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 2010;39(1):D913-9.

Pédron B, Yakouben K, Guérin V, Borsali E, Auvrignon A, Landman J, et al. HLA alleles and haplotypes in French North African immigrants. Human Immunol. 2006;67(7):540-50.

Mahfoudh N, Ayadi I, Kamoun A, Ammar R, Mallek B, Maalej L, et al. Analysis of HLA-A,-B,-C,-DR,-DQ polymorphisms in the South Tunisian population and a comparison with other populations. Ann Human Biol. 2013;40(1):41-7.

Fabio G, Scorza R, Lazzarin A, Marchini M, Zarantonello M, D'arminio A, et al. HLA‐associated susceptibility to HIV‐1 infection. Clin Exp Immunol. 1992;87(1):20-3.